Pharvaris N.V. (PHVS) Income Statement

The revenue line is consistently zero, confirming the company's clinical-stage status and lack of commercial products. The primary trajectory is the scaling of R&D expenditure, which appears to be driven by the advancement of the CHAPTER and RAPIDe clinical programs. This pattern suggests management is executing on its development timeline, but it also implies a prolonged period of cash consumption before any potential revenue generation.

R&D is the clear primary cost driver, reflecting the capital-intensive nature of late-stage clinical trials. The steady increase in SG&A, from $9.8M in 2024Q1 to $15.8M in 2026Q2, appears to be a necessary investment in building the operational infrastructure for a future launch. The cost discipline is evident in the controlled growth of SG&A relative to the more volatile R&D line, suggesting management is prioritizing clinical execution over administrative overhead.

Without revenue to absorb fixed costs, every incremental dollar of R&D spending directly increases the operating loss. The operating margin is structurally negative and will remain so until commercial revenue is achieved. This dynamic highlights the binary nature of the investment; the company must successfully navigate its clinical trials to reach a point where revenue can cover this substantial fixed-cost base.

This event represents a critical operational inflection point, as it de-risks the development timeline for the lead prophylactic candidate. The subsequent increase in R&D spending in 2026Q1 and 2026Q2 likely reflects the resumption and acceleration of trial activities. This inflection shifts the primary risk from regulatory uncertainty to clinical and commercial execution, setting the stage for the next major catalysts: data readouts and potential approval.